65th ASH Annual Meeting & Exposition: ASH-FDA Joint Symposium I: Targeted, Gene and Cellular Therapy - Recent Approvals in Non-Malignant Hematology

Special-Interest Sessions

Therapies

Room 7 (San Diego Convention Center)

Chair:

Donna A. Whyte-Stewart, MD, MSc, Food and Drug Administration

Disclosures:

No relevant conflicts of interest to declare.

Introduction

Donna A. Whyte-Stewart, MD, MSc

DNH/OCHEN/CDER, Food and Drug Administration, Silver Spring, MD

Cellular Therapy and HSCT Mobilizers – Omidubicel-onlv

Najat Bouchkouj, MD

Division of Clinical Evaluation Hematology, Office of Therapeutic Products (OTP), Center for Biologics Evaluation and Research (CBER), US Food and Drug Administration, Silver Spring, MD

Cellular Therapy and HSCT Mobilizers – Motixafortide

Donna A. Whyte-Stewart, MD, MSc

DNH/OCHEN/CDER, Food and Drug Administration, Silver Spring, MD

Clinical Discussant for Transplant

Navneet Majhail, MD, MS, FASTCT

Sarah Cannon Transplant and Cellular Therapy Network, Nashville, TN

Momelotinib for Myelofibrosis

Alison R. Moliterno, MD

DNH/OCHEN/CDER, Food and Drug Administration, Silver Spring, MD

Clinical Discussant for Myelofibrosis

Jeanne Palmer, MD

Mayo Clinic - Arizona, Scottsdale, AZ

Gene Therapy and Editing

Nicole Verdun, MD

CBER, Food and Drug Administration, Silver Spring, MD

Clinical Discussant on Gene Therapy and Editing

Punam Malik, MD

Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Discussion Panel

Donna A. Whyte-Stewart, MD, MSc

DNH/OCHEN/CDER, Food and Drug Administration, Silver Spring, MD

See more of: Special-Interest Sessions

<< Previous Session | Next Session >>